Podcasts about Inhibitor

Did you know that a single crumb of bread is enough to cause an autoimmune response in children with celiac disease? Dr. Pankaj Vohra, Professor of Pediatrics and Board-Certified Pediatric Gastroenterologist, joins medical student Andrea Smith to discuss the evaluation and management of celiac disease, as well as essential guidance for following a gluten-free diet. Specifically, they will: Review the epidemiology of celiac disease and identify common symptoms and presentations of celiac disease Describe the pathophysiology of celiac disease including histopathological changes to the duodenum Identify diagnostic tests and criteria for diagnosing celiac disease in the pediatric population Identify common sources of gluten and the basics of identifying gluten on food labels Discuss typical management of celiac disease including appropriate screening tests and managing accidental gluten ingestion Special thanks to Dr. Rebecca Yang and Dr. Neeharika Bade for peer reviewing this episode. CME available free with sign up: Link coming soon! References: Bolia, R., & Thapar, N. (2023). Celiac Disease in Children: A 2023 Update. In Indian Journal of Pediatrics. Springer. https://doi.org/10.1007/s12098-023-04659-w Gidrewicz, D., Potter, K., Trevenen, C. L., Lyon, M., & Butzner, J. D. (2015). Evaluation of the ESPGHAN celiac guidelines in a North American pediatric population. American Journal of Gastroenterology, 110(5), 760–767. https://doi.org/10.1038/ajg.2015.87 Hill, I. D., Fasano, A., Guandalini, S., Hoffenberg, E., Levy, J., Reilly, N., & Verma, R. (2016). NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 156–165. https://doi.org/10.1097/MPG.0000000000001216 Husby, S., Koletzko, S., Korponay-Szabó, I., Kurppa, K., Mearin, M. L., Ribes-Koninckx, C., Shamir, R., Troncone, R., Auricchio, R., Castillejo, G., Christensen, R., Dolinsek, J., Gillett, P., Hróbjartsson, A., Koltai, T., Maki, M., Nielsen, S. M., Popp, A., Størdal, K., … Wessels, M. (2020). European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. In Journal of Pediatric Gastroenterology and Nutrition (Vol. 70, Issue 1, pp. 141–156). Lippincott Williams and Wilkins. https://doi.org/10.1097/MPG.0000000000002497 Nenna, R., Tiberti, C., Petrarca, L., Lucantoni, F., Mennini, M., Luparia, R. P. L., Panimolle, F., Mastrogiorgio, G., Pietropaoli, N., Magliocca, F. M., & Bonamico, M. (2013). The celiac iceberg: Characterization of the disease in primary schoolchildren. Journal of Pediatric Gastroenterology and Nutrition, 56(4), 416–421. https://doi.org/10.1097/MPG.0b013e31827b7f64 Sahin, Y. (2021). Celiac disease in children: A review of the literature. In World Journal of Clinical Pediatrics (Vol. 10, Issue 4, pp. 53–71). Baishideng Publishing Group Co. https://doi.org/10.5409/wjcp.v10.i4.53 Salden, B. N., Monserrat, V., Troost, F. J., Bruins, M. J., Edens, L., Bartholomé, R., Haenen, G. R., Winkens, B., Koning, F., & Masclee, A. A. (2015). Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Alimentary Pharmacology and Therapeutics, 42(3), 273–285. https://doi.org/10.1111/apt.13266 Schuppan, D., Mäki, M., Lundin, K. E. A., Isola, J., Friesing-Sosnik, T., Taavela, J., Popp, A., Koskenpato, J., Langhorst, J., Hovde, Ø., Lähdeaho, M.-L., Fusco, S., Schumann, M., Török, H. P., Kupcinskas, J., Zopf, Y., Lohse, A. W., Scheinin, M., Kull, K., … Greinwald, R. (2021). A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 385(1), 35–45. https://doi.org/10.1056/nejmoa2032441 Tack, G. J., van de Water, J. M. W., Bruins, M. J., Kooy-Winkelaar, E. M. C., van Bergen, J., Bonnet, P., Vreugdenhil, A. C. E., Korponay-Szabo, I., Edens, L., von Blomberg, B. M. E., Schreurs, M. W. J., Mulder, C. J., & Koning, F. (2013). Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World Journal of Gastroenterology, 19(35), 5837–5847. https://doi.org/10.3748/wjg.v19.i35.5837 Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136–160

Special Edition of the JAMA Editor's Summary featuring JAMA Network articles published at the 2025 AHA Scientific Sessions. Hosted by JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation DASH-Patterned Groceries and Effects on Blood Pressure Coronary Computed Tomography Angiography in Prediction of First Coronary Events Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy Clonal Hematopoiesis and Incident Heart Failure Chronic Kidney Disease Prevalence and Awareness Among US Adults Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer Prenatal Care and Perinatal Regionalization for Congenital Heart Defects Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

In this episode, Lindsey speaks with Tyrone Folliard-Olson. Tyrone is a husband, father and Vice Chair of the board for the National Alopecia Areata Foundation. He has had alopecia since age 13. Tyrone shares openly about not only coming to terms with his alopecia but about simultaneously coming out of the closet as gay. He details meeting his now husband in college and adopting their son Declan. Plus, Tyrone talks about getting to a place where he felt strong enough to want to help others struggling with alopecia AND like Lindsey, making the complicated decision to go on a JAK inhibitor.

For decades, allergists have focused on blocking what happens outside the mast cell: histamine, IgE, and interleukins. But now, there's a new way to stop allergic inflammation before it even starts: by targeting what happens inside the cell with BTK Inhibitors. Dr. Payel Gupta and Kortney are joined by Dr. Matthew Giannetti to unpack what BTK actually does and why inhibiting it represents an exciting breakthrough in allergy and immunology. Together, they explore how BTK inhibitors work, why this inside-the-cell approach is different from anything before, and what it could mean for people living with chronic spontaneous urticaria (CSU). What the episode covers about BTK inhibitors: BTK explained: Bruton's tyrosine kinase is a pivotal “last step” before mast-cell degranulation. How BTK inhibitors work: Blocking BTK can stop histamine release downstream of many outside triggers. The science: Why BTK binding is irreversible for each molecule and how the body “re-makes” BTK over time. Safety in brief: A look at petechiae (small pinpoint spots), what to monitor, and how shared decision-making guides treatment choices. The future of BTK inhibitors: Exploring their potential role in other allergic conditions.    ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

In this episode of HSS Presents, rheumatologist Dr. Anne Bass is joined by Dr. Deanna Jannat-Khah of HSS and Dr. Michael Postow of Memorial Sloan Kettering to explore immune checkpoint inhibitor–induced arthritis. They discuss how life-saving immunotherapies for cancer can trigger inflammatory joint disease, the challenges of balancing tumor control with autoimmune toxicity, and the latest evidence on safe use of steroids and biologics. The panel also highlights ongoing research into mechanisms, phenotypes, and long-term outcomes, underscoring the importance of multidisciplinary care for cancer patients who develop musculoskeletal complications from immunotherapy.

In today's episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.   In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Yinghong Wang, MD, PhD, MS Immune checkpoint inhibitor (ICI) colitis comes with unique diagnostic and treatment challenges, which means that recognizing and managing it effectively is key to the best outcomes. Joining Dr. Peter Buch to share her insights on caring for patients with this complex condition is Dr. Yinghong Wang. Dr. Wang is a Professor in the Department of Gastroenterology, Hepatology, and Nutrition at MD Anderson Cancer Center in Houston, Texas, as well as Director of the Oncology-GI Toxicity Program, Director of Fecal Microbiota Transplantation, Deputy Division Head of Research in the Division of Internal Medicine, and Chair of the MD Anderson Cancer Center Immunotherapy Toxicity Working Group.

Contributor: Ricky Dhaliwal, MD Educational Pearls: Angioedema in anaphylaxis Histamine and mast cell-mediated pathway Treatment: First line: epinephrine for vasoconstriction and bronchodilation Second line: H1 and H2 antihistamines such as Benadryl and famotidine ACE inhibitor-induced angioedema Different pathway from anaphylaxis ACE inhibitor-induced angioedema is mediated by bradykinins Therefore, anaphylaxis medications are not beneficial in patients with ACE inhibitor-induced angioedema Leading cause of drug-induced angioedema in the US Patients most commonly present with swelling of the lips, tongue, or face Treatment: Airway management: varies depending on the severity and progression of the presentation If awake nasointubation is required, LMX is a 5% lidocaine water-soluble solution that provides anesthesia to the oropharynx Medications: Icatibant is a synthetic bradykinin B2-receptor antagonist that can be used in acute treatment Tranexamic acid (TXA) inhibits the plasmin-dependent formation of bradykinin, but the data on this treatment are mixed and limited Fresh frozen plasma (FFP) is thought to degrade high levels of bradykinin with subsequent resolution of angioedema Discontinue ACE inhibitor References Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009 Jul;124(1):129-34. doi: 10.1016/j.jaci.2009.03.038. Epub 2009 May 27. PMID: 19477491. Bova M, Guilarte M, Sala-Cunill A, Borrelli P, Rizzelli GM, Zanichelli A. Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med. 2015 Apr;10(3):345-50. doi: 10.1007/s11739-015-1205-9. Epub 2015 Feb 10. PMID: 25666515. Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol. 2002 Feb;109(2):370-1. doi: 10.1067/mai.2002.121313. PMID: 11842313. Pathak GN, Truong TM, Chakraborty A, Rao B, Monteleone C. Tranexamic acid for angiotensin-converting enzyme inhibitor-induced angioedema. Clin Exp Emerg Med. 2024 Mar;11(1):94-99. doi: 10.15441/ceem.23.051. Epub 2023 Aug 1. PMID: 37525579; PMCID: PMC11009700. Simons FE. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol. 2004 May;113(5):837-44. doi: 10.1016/j.jaci.2004.01.769. Erratum in: J Allergy Clin Immunol. 2004 Jun;113(6):1039. Dosage error in article text. PMID: 15131564. Summarized by Meg Joyce, MS2 | Edited by Meg Joyce & Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

Effective management of adverse events and addressing barriers to care are critical to optimizing outcomes and maintaining quality of life for patients receiving CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Julia Lea Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator in solid tumor oncology at Atrium Health Levine Cancer Institute about proactive, team-based strategies to identify, monitor, and manage treatment-related toxicities in patients with early-stage and metastatic HR-positive, HER2-negative breast cancer. Dr. Ziegengeist sheds light on the patient journey, the roles of various multidisciplinary care team members, and useful resources for language and literacy barriers. “I think the biggest thing that is specific to CDK4/6 inhibitors is... eligibility criteria and when we're using the drugs in what setting, having those monitoring protocols and getting that multidisciplinary collaboration is really key.” – Julia Lea Ziegengeist, PharmD, BCOP   Julia Lea Ziegengeist, PharmD, BCOP   Clinical Pharmacist Coordinator, Solid Tumor Oncology   Levine Cancer Institute   Atrium Health   Charlotte, NC       Resources: ACCC Resource: CDK4/6 Inhibitors Management  ACCC CDK4/6 Inhibitors Infographic 

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Download the transcript here

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Listen to the podcast here

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

BUFFALO, NY - August 13, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.” In this study, led by first author Jassy Mary S. Lazarte and corresponding author Nazarius S. Lamango from Florida A&M University College of Pharmacy and Pharmaceutical Sciences, researchers investigated a new class of compounds called polyisoprenylated cysteinyl amide inhibitors (PCAIs) as a potential treatment for aromatase inhibitor (AI) therapy resistant breast cancer. Aromatase inhibitors are a common treatment for estrogen receptor-positive (ER+) breast cancer, but many patients eventually develop resistance, leaving fewer therapeutic options. The study focused on a PCAI compound called NSL-YHJ-2-27, which was tested in long-term letrozole-treated breast cancer cells (LTLT-Ca), an experimental model of AI therapy resistance. NSL-YHJ-2-27 activated two major signaling pathways, MAPK and PI3K/AKT. Although these pathways typically support cancer cell survival, their overstimulation by PCAIs led to increased oxidative stress, damaging the cells and inducing cell death by apoptosis. The compound also reduced levels of RAC1 and CDC42, proteins involved in maintaining cell shape and movement. These alterations resulted in cytoskeletal disruption and reduced structural integrity, making the cancer cells more vulnerable and less capable of spreading. Importantly, the effects of NSL-YHJ-2-27 persisted after the compound was removed, suggesting long-term control over AI resistant cancer cells may be possible. “PCAIs inhibited cell proliferation and colony formation by 95% and 74%, respectively, increased active caspase 7 and BAX 1.5-fold and 56%, respectively. NSL-YHJ-2-27 (10 μM) induced LTLT-Ca spheroid degeneration by 61%.” As a new class of targeted molecules, PCAIs represent an innovative approach distinct from traditional endocrine therapies. Their ability to affect multiple cellular mechanisms simultaneously makes them promising candidates for future drug development. Overall, this study presents a promising new approach for treating AI therapy-resistant breast cancer. By targeting cellular pathways that support survival and mobility, PCAIs like NSL-YHJ-2-27 could provide a novel strategy to manage advanced or resistant forms of the disease. Further research, including in vivo studies and clinical trials, will be essential to confirm these findings and evaluate their therapeutic potential. DOI - https://doi.org/10.18632/oncotarget.28759 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Video short - https://www.youtube.com/watch?v=8xQEilloO9Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28759 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, ROS, MAPK, PI3K/AKT, LTLT-Ca cells To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle and dietary techniques to improve tolerance of this treatment.   Diana Van Ostran, PharmD, BCOP  Clinical Pharmacy Specialist – Breast Clinic Miami Cancer Institute Baptist Health South Florida  Miami, FL   “Clinical pharmacists play a vital role in managing the patient's treatment. Because, as we know, if you're having excessive side effects, patients are going to be less likely to take their medications.”   Resources: ACCC Adverse Event Management for CDK Inhibitors in HR+ Breast Cancer ACCC CDK Inhibitors Management Miami Cancer Institute ACCC Spotlight on Miami Cancer Institute: The Role of a Breast Cancer Clinical Pharmacy Specialist for CDK4/6 Inhibitor Management

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC). Episode Highlights: • Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib. • Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life. • Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications. • Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies. • Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies. Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and platelets under arterial shear conditions. Investigators say it's a novel biophysical mechanism that potentially contributes to post-vaccination arterial thrombosis. Finally, we explore lineage switch, an emerging form of acute leukemia relapse with dismal outcomes. It arises rapidly following antigen-targeted immunotherapy, highlighting the importance of advanced methods for detection and treatment.Featured Articles: Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 studyShear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosisProject EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

In this episode, we discuss the evidence, safety, and place in therapy of Journavx® (suzetrigine), a newly approved analgesic with a unique non-opioid mechanism of action and additional considerations for its use. Key Concepts Suzetrigine is a first in its class NaV1.8 sodium channel blocker approved for short-term (14 days or less) pain relief in adults with moderate-to-severe pain. Unlike opioids, suzetrigine is non-sedating and non-dependence forming. Suzetrigine is taken as a whole pill without cutting, crushing, or chewing following a particular dosing schedule where the first dose is taken on an empty-stomach.  The most common side effects of suzetrigine include pruritus, muscle spasms, increased CPK, rash, and transient (reversible) eGFR decrease. Suzetrigine goes through CYP3A metabolism and therefore has significant interactions with CYP3A inducers and inhibitors. Use with strong inhibitors and moderate to strong inducers is not recommended. Dose reduction of suzetrigine is required if used with moderate inhibitors of CYP3A.  Although not formally adopted in a guideline recommendation, suzetrigine's current place in therapy can be moderate-to-severe acute pain relief in adult patients after NSAIDs/APAP options are exhausted, but before or in place of opioid therapy.  References Bertoch T, D'Aunno D, McCoun J, et al. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025;142(6):1085-1099. doi:10.1097/ALN.0000000000005460

Discover the future of pain management on this episode of Atomic Anesthesia as we explore a major breakthrough: the FDA approval of suzetrigine, a first-in-class, nonopioid pain medication. Guided by cutting-edge research and expert editorial insight from Anesthesiology, we dig into how suzetrigine works—targeting the NaV1.8 sodium channel in peripheral nerves—and what this means for patients and providers facing acute pain. You'll hear about the pivotal NAVIGATE clinical trials, real-world patient experiences, and the medication's advantages over traditional opioids, including fewer side effects and no risk of addiction. Whether you're a healthcare professional, patient, or someone passionate about medical innovation, join us to learn how suzetrigine is poised to reshape pain relief and help bridge the gap left by the opioid crisis.References:Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PMID: 40117446; PMCID: PMC12061372.Rathmell JP, Clark JD, Eisenach JC. Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain. Anesthesiology. 2025 Jun 1;142(6):989-991. doi: 10.1097/ALN.0000000000005465. Epub 2025 May 13. PMID: 40358331.

Efficacy And Safety of AZD0780, An Oral Small Molecule PCSK9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Associate Editor Marius Hoeper about the efficacy and safety of the activin signalling inhibitor sotatercept in a pooled analysis of PULSAR and STELLAR studies.

Moderator: James P. Rathmell, M.D. Participants: Carmen Bozic, M.D. Articles Discussed: Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

Sodium Glucose Cotransporter-2 Inhibitors (SGLT2) have demonstrated improvement in patient outcomes across several disease states including patients with type 2 diabetes, heart failure and chronic kidney disease.  Despite guideline recommendations for the use of these agents in each of these disease states, utilization of SGLT2 remains relatively low. This podcast discusses some of the barriers to utilization of SGLT2 and strategies to increase uptake of this therapy among patients with diabetes, heart failure and chronic kidney disease.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://auau.auanet.org/node/42822 At the conclusion of this CME activity, participants will be able to: 1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer. 2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy. 3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes. 4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing. 5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination. ACKOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Merck & Co., Inc.

Because of breast cancer, fear of cancer recurrence is a permanent part of my life. I continue taking tamoxifen to reduce my risk of the cancer coming back. In this episode I share my thoughts on the good quality of life I have while taking tamoxifen. I value my strong body and theimited side-effects I have now. I also value a life with the lowest possible risk of breast cancer recurrence. I look forward to discussing what it might mean to switch to an aromatase inhibitor, in terms of further lowering the risk of recurrence and potentially experiencing more serious side-effects, with my oncologist  On more than one occasion, the oncologist has brought up endocrine therapy and the possibility of switching from tamoxifen to an aromatase inhibitor “in the future”.  Even my breast surgeon provided a quick plug for the lower risk of recurrence associated with taking aromatase inhibitors, compared to tamoxifen, without highlighting any of the aromatase inhibitor side-effects.  Determining what might be the best endocrine therapy for me to prevent recurrence is not going to be easy.  So far, neither doctor has done a deep dive into the different side-effects among the two drugs or what a change might do to overall health and quality of life.   Thank you for listening to my story! If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list! LET'S CONNECT: connect@breastcancerlife.org  Follow us on Pinterest 

Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma.The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA). K9-ACV has safely been used in over 1,000 dogs, and the vaccine has been shown to display safety in a previous study (without the addition of the checkpoint inhibitor). By evaluating K9-ACV, this trial aims to advance safer, immune-based treatment options for canine cancer that may offer comparable or superior outcomes to chemotherapy.Find more information about this study:https://studypages.com/s/autologous-cancer-vaccine-with-checkpoint-inhibitor-for-treatment-of-canine-osteosarcoma-565406/Adrienne Wright, adrienne@ardentanimalhealth.com, +1 (859) 619-5893

Discover the neurobiological secrets of revitalizing your mental battery with Michael Nehls, Ph.D. Learn how to harness the fountain of our mental energy, creativity, individuality, and motivation for better performance and well-being. Optimize your brain's potential today! #MentalEnergy #Neurobiology #Motivation

Show notes at pharmacyjoe.com/episode1018. In this episode, I'll discuss andexanet vs. prothrombin complex concentrate for reversal of factor Xa inhibitor-related intracranial hemorrhage. The post 1018: Balancing Risk vs Benefit – Andexanet vs. Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage appeared first on Pharmacy Joe.

Commentary by Dr. Jafar Al-Mondhiry.

Commentary by Dr. Katie Ruddy.

JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.

Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach. A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/

Prothrombin complex concentrates (PCCs) are frequently used off label for the management of factor Xa inhibitor-associated major bleeding. In 2018, accelerated approval was granted for andexanet alfa, a specific factor Xa inhibitor reversal agent, for reversal of apixaban and rivaroxaban in the setting of life-threatening or uncontrolled bleeding. Following accelerated approval, some clinical practice guidelines were updated to include recommendations for andexanet alfa preferentially over PCCs for reversal of life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban. Other guidelines stated no preference of andexanet alfa over PCC. In 2020, Vizient convened an expert panel to critically appraise the literature and provide consensus-based, expert opinions on the utilization of pharmacological reversal agents for factor Xa-related major bleeding. Since then, the body of literature evaluating these agents has expanded to include a randomized controlled trial, ANNEXa-I, the results of which were submitted to the US Food and Drug Administration to convert the approval of andexanet alfa from accelerated to full approval. Dr. Lisa Baumann-Kreuziger, Associate Professor of Hematology and Oncology, Medical College of Wisconsin and medical director of the Antithrombotic Therapy Management Program at Froedtert Health discusses the current status of management of factor Xa inhibitor-associated major bleeding with Dr. Kerry Schwarz, Senior Clinical Manager of Evidence-Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, and your program host.   Guest speakers:  Liza Baumann-Kreuziger, MD, MS Investigator, Blood Research Institute, Versiti  Associate Professor of Hematology and Oncology, Medical College of Wisconsin Medical Director, Antithrombotic Therapy Management Program at Froedtert Health   Host:  Kerry Schwarz, Pharm.D, MPH Senior Clinical Manager of Evidence-Based Medicine and Outcomes  Vizient Center for Pharmacy Practice Excellence   Show Notes: [02:25-04:26] The current state of hemostatic management in the setting of factor Xa inhibitor-related major bleeding [04:27- 05:35] Limitations of available evidence making clinical practice and formulary decision making so challenging [05:35 – 10:52] Publication of the first randomized controlled trial, ANNEXa-I, comparing andexanet alfa to usual care [10:52-14:49] Meeting of the FDA advisory committee and subsequent complete response letter [14:50-16:45] How we can approach clinical management of patients and formulary decision-making in the current state   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Susan Svoboda was accustomed to going in for her mammogram every November.  She enjoyed a healthy lifestyle, which included running 65 half marathons.  But in late 2021, after her mammogram, she was called to return to the doctor's office.  After scans and a biopsy, she was diagnosed with Stage 1-2 invasive ductal carcinoma.   Given her healthy routine, Susan was shocked, but she quickly had to turn her attention to her treatment.  In 2022, she underwent a successful lumpectomy.  Because of the location of the lump, and her low Oncotype DX score, the oncologist told Susan she would not have to undergo chemotherapy.  Instead, she would need to get radiation treatment, 15 rounds over three weeks; but her oncologist also suggested her regimen include estrogen inhibitor pills for the next five years.   Susan consulted reading materials and talked to numerous women who had tried the pills.  All of them had something to say that helped her to make the difficult decision to refuse the estrogen inhibitors.   Susan Svoboda found her way to survivorship.  She says that while she doesn't do half marathons, she still some light running and goes walking every day. Her journey inspired her to spend 2022 writing a book, “I Hate The Color Pink.”  She says the satisfaction that comes from writing the book is its spreading a message of information and hope.   By way of advise, Susan advises women to get their mammograms and when dealing with doctors to ask questions, lots of questions.   Addition Resources:   Susan Book, available on Amazon: “I Hate The Color Pink”

On this episode of the Astonishing Healthcare podcast, Justin Venneri chats with Angela Kalantarova, PharmD, a senior clinical programs manager at Capital Rx, about recent updates to Medicare's star ratings. Angela shares her path to Capital Rx and experience working in managed care and on clinical programs, and she explains what's new for 2025: star measures for polypharmacy and concurrent use of opioids and benzodiazepines.The conversation highlights the positive impact early interventions can have and how innovative enterprise health technology like Judi® allows for real-time insights. As CMS proposes changes, such as possibly removing the MTM - medication therapy management - measure or others like limiting initial opioid supply, having the flexibility to react quickly helps immensely. Angela also provides some strategic insights into how to navigate the evolving landscape and achieve superior ratings.Related ContentAH035 - Pharmacy Benefits 101: Clinical Programs, with Bonnie Hui-Callahan, PharmDPoster: Impact of Point-of-Sale Duplicate Therapy Safety Alert on Concomitant DPP-4 Inhibitor and GLP-1 Agonist UseAH005 - Star Ratings, MTM, & CMS Translation Requirements with Jay Tran, PharmDAH006 - Pharmacy Benefits 101: Clinical Care Teams, with Amy Stockton, PharmDFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

This episode of JACC-Baran features a brief discussion on Kendrick Lamar and the history of racial discrimination in the United States. Then Hiroki Ueyama, MD, from Emory University discusses his study on P2Y12 inhibitor pre-treatment in NST-ACS using data from the Chest Pain-MI Registry. The study examines how guideline changes have influenced clinical practice, revealing a decline in pre-treatment rates, significant practice variations, and no major differences in outcomes except for longer hospital stays in CABG patients. Watch the video or listen as a podcast here, then check out the JACC article: https://www.jacc.org/doi/10.1016/j.jacc.2024.09.1227

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we cover immune checkpoint inhibitors and adverse events. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

In this podcast, Dr. Valentin Fuster discusses a study on the use of P2Y12 inhibitor pretreatment in patients with non-ST elevation acute coronary syndrome, revealing significant variability in its application across institutions and operators. Despite initial hypotheses of benefit, the findings indicate no significant difference in patient outcomes, suggesting that routine pretreatment may not be necessary, especially when treatment is initiated within 24 hours of symptom onset.

Sodium–glucose cotransporter (SGLT) 2 inhibitors are an exciting new class of drugs approved for the treatment of newly diagnosed diabetic cats. These drugs work by blocking the kidneys from reabsorbing glucose, which causes more glucose to be lost in urine and lowers blood glucose levels. Tune in to this episode of the VetFolio Voice podcast as host Dr. Cassi and her guest, Dr. Audrey Cook, explore when to consider an SGLT-2 inhibitor instead of insulin and how to successfully manage and monitor a cat receiving this treatment.

Clone Wars Conversations continues with a vital arc to understanding what actually happened in Order 66; the first four episodes of Season 6! Dave, Maff & Mike talk in-depth about the clone inhibitor chips, Fives and more! In this episode, the trio discuss the premiere of the “final” season (before Season 7 was announced/released) and how this series has brought such life to the many clones, including Fives. They talk about the depth of the conspiracy, Palpatine, the droid AZ, Kamino and what these episodes mean for Revenge Of The Sith & beyond (without detailing Bad Batch, as Dave & Maff have yet to see it). Episodes featured; The Unknown, Conspiracy, Fugitive & Orders. The weekly Skeleton Crew discussion shows continue, with Maff on the episode 4 talk and Dave to appear in 2025! Listen on any podcast app: https://pod.fo/e/29345d or watch on YouTube: https://youtu.be/Q7yoQ0NnjgI Clone Wars Conversations has been releasing monthly since January 21st 2024 on the usual podcast feeds & YouTube (eps 221, 225, 229, 233, 236, 238, 241, 244, 245, 249, 251 & 252 of GCC): https://www.youtube.com/playlist?list=PLcO1Ib_BGD8Y79aRWUxSWwdy3eyNrbXBl   The trio are all featuring in various episodes of JAC's Back to The Filmography, each of their first season 2 appearances are out now, for the season of Matthew McConaughey! Dave talks about Dazed & Confused, Maff does Angels In The Outfield and Mike does Glory Daze! Listen to BttF anywhere you find podcasts: https://podfollow.com/1686261095    Mike appeared on Spider-Dan & The Secret Bores for their top 5 small cast movies, listen here: https://pod.fo/e/289237 Mike also appeared on Spider-Dan's pod with Megan, talking Princess Diana in Spencer: https://pod.fo/e/2916c6 Maff is @MaffUK78 on Twitter and recently spoke about Conan comics on 20th Century Geek here: https://pod.fo/e/277fbc - spoke about the TMNT story The Last Ronin on Indie Comics Spotlight here: https://pod.fo/e/24c64a - and did a spider-related podcast with Spider-Dan here: https://pod.fo/e/22733f You can find Dave on Threads @davehorrocks, or the podcasts Comics In Motion, the VHS Strikes Back: https://linktr.ee/vhsstrikesback and Chris & Dave's Reality TV Cast: https://anchor.fm/cdrealitycast  Last week on Genuine Chit-Chat & Comics In Motion, Mike interviewed Charles Soule & Ryan Browne about their upcoming Lucky Devils comic! Listen here: https://pod.fo/e/291d48 or watch the video version here: https://youtu.be/K4sUI_zU9L4   Mike has been involved with many other Star Wars podcasts, including interviewing Mike Chen on episode 234 of GCC about his novel Star Wars: Brotherhood and he returns on episode 246 to talk about his latest novel with Marvel; What If Marc Spector Was Host To Venom? Ep 234 found here: https://pod.fo/e/23d985 & https://youtu.be/pQA0QvC5qa0 and ep 246 found here: https://pod.fo/e/279547 & https://youtu.be/PAEmwuhG2gw Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Timestamps: 00:00 Intro, Guest Spots & What's To Come 03:02 Season 6 P1 Discussion 01:34:00 Outro

Clone Wars Conversations continues with a vital arc to understanding what actually happened in Order 66; the first four episodes of Season 6! Dave, Maff & Mike talk in-depth about the clone inhibitor chips, Fives and more! In this episode, the trio discuss the premiere of the “final” season (before Season 7 was announced/released) and how this series has brought such life to the many clones, including Fives. They talk about the depth of the conspiracy, Palpatine, the droid AZ, Kamino and what these episodes mean for Revenge Of The Sith & beyond (without detailing Bad Batch, as Dave & Maff have yet to see it). Episodes featured; The Unknown, Conspiracy, Fugitive & Orders. The weekly Skeleton Crew discussion shows continue, with Maff on the episode 4 talk and Dave to appear in 2025! Listen on any podcast app: https://pod.fo/e/29345d or watch on YouTube: https://youtu.be/Q7yoQ0NnjgI Clone Wars Conversations has been releasing monthly since January 21st 2024 on the usual podcast feeds & YouTube (eps 221, 225, 229, 233, 236, 238, 241, 244, 245, 249, 251 & 252 of GCC): https://www.youtube.com/playlist?list=PLcO1Ib_BGD8Y79aRWUxSWwdy3eyNrbXBl   The trio are all featuring in various episodes of JAC's Back to The Filmography, each of their first season 2 appearances are out now, for the season of Matthew McConaughey! Dave talks about Dazed & Confused, Maff does Angels In The Outfield and Mike does Glory Daze! Listen to BttF anywhere you find podcasts: https://podfollow.com/1686261095    Mike appeared on Spider-Dan & The Secret Bores for their top 5 small cast movies, listen here: https://pod.fo/e/289237 Mike also appeared on Spider-Dan's pod with Megan, talking Princess Diana in Spencer: https://pod.fo/e/2916c6 Maff is @MaffUK78 on Twitter and recently spoke about Conan comics on 20th Century Geek here: https://pod.fo/e/277fbc - spoke about the TMNT story The Last Ronin on Indie Comics Spotlight here: https://pod.fo/e/24c64a - and did a spider-related podcast with Spider-Dan here: https://pod.fo/e/22733f You can find Dave on Threads @davehorrocks, or the podcasts Comics In Motion, the VHS Strikes Back: https://linktr.ee/vhsstrikesback and Chris & Dave's Reality TV Cast: https://anchor.fm/cdrealitycast  Last week on Genuine Chit-Chat & Comics In Motion, Mike interviewed Charles Soule & Ryan Browne about their upcoming Lucky Devils comic! Listen here: https://pod.fo/e/291d48 or watch the video version here: https://youtu.be/K4sUI_zU9L4   Mike has been involved with many other Star Wars podcasts, including interviewing Mike Chen on episode 234 of GCC about his novel Star Wars: Brotherhood and he returns on episode 246 to talk about his latest novel with Marvel; What If Marc Spector Was Host To Venom? Ep 234found here: https://pod.fo/e/23d985 & https://youtu.be/pQA0QvC5qa0 and ep 246 found here: https://pod.fo/e/279547 & https://youtu.be/PAEmwuhG2gw Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Timestamps: 00:00 Intro, Guest Spots & What's To Come 03:02 Season 6 P1 Discussion 01:34:00 Outro

When a new drug class enters the veterinary world, first comes the excitement…then comes the learning. In this episode of Clinician's Brief Partner Podcast, Jocelyn Mott, DVM, DACVIM, answers your most frequently asked questions when it comes to using a novel drug class in the treatment of feline diabetes mellitus: the sodium-glucose cotransporter-2 inhibitor. Tune in as she explains when, how, and why to consider this option in newly diagnosed feline diabetics.Sponsored by ElancoResource:https://my.elanco.com/us/bexacatContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing

JACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among those undergoing CABG, underscoring the importance of maintaining efforts to integrate evidence into clinical practice.

On this episode of the Real Life Pharmacology podcast, I cover medications 51-55. They are eszopiclone, celecoxib, estrogen, moxifloxacin, and donepezil. Eszopiclone is a "Z" drug used for insomnia. Its adverse effect profile is very similar to benzodiazepines. Celecoxib is a COX-2 Inhibitor used for pain and inflammation. I discuss how this medication differs from traditional NSAIDs. Estrogen therapy is used for menopausal symptoms but carries a risk of cancer and blood clots. Moxifloxacin is a quinolone antibiotic. Binding drug interactions, boxed warnings, and QTc prolongation are potential concerns. Donepezil is a medication used for dementia. I discuss its mechanism of action and common adverse effects.